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PURPOSE: The aim of the study is to determine period and birth-cohort effects in the early initiation of
phencyclidine (PCP) use in drug users in New York City (NYC).
METHODS: We analyzed data collected from two surveys of street-recruited drug users in NYC. We used
survival analysis and proportional hazards modeling to assess period and birth-cohort effects on risk for early
initiation of PCP use.
RESULTS: Of 787 participants, 292 (37.1%) had used PCP by the age of 23 years. Before 1987, there was
a greater risk for initiation of PCP use through the age of 23 years (hazard ratio [HR] Z 34.77; 95% con-
fidence interval [CI], 21.45–56.36). Proportional hazards modeling showed that those born in the 1971 to
1975 birth cohort compared with those born in 1976 to 1980 had a lower risk for initiation of PCP use
through age 23 years (HR Z 0.58; 95% CI, 0.37–0.91). Other significant predictors of PCP use by age
23 included white race and having been in a juvenile detention center.
CONCLUSIONS: There are period and birth-cohort differences in the likelihood of early initiation of
PCP use. Changes in drug culture and social norms may influence the likelihood of initiation of PCP
use. This may have implications for interventions aimed at slowing the nationwide increase in use of PCP.
Ann Epidemiol 2006;16:266–272.  2006 Elsevier Inc. All rights reserved.
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The National Institute on Drug Abuse defines ‘‘club drugs’’
as ‘‘drugs used by teens and young adults who are part of
a nightclub, bar, rave, or trance scene’’ (1). These drugs
typically include MDMA (ecstasy), phencyclidine (PCP),
gamma hydroxybutyrate, rohypnol, amphetamines, lysergic
acid diethylamide (LSD), and ketamine (1, 2). Reports
suggested there may be a resurgence of club-drug use in the
United States (3–5). Drug Enforcement Agency (DEA)
reports trace the beginning of this increase to the mid
to late 1990s (6). PCP has been one of the main drugs impli-
cated in the return of club drug use (2). PCP has been used as
a recreational drug since the late 1960s, although it
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360 Park Avenue South, New York, NY 10010originally was developed for medical and surgical use as an
anesthetic. It is classified as a dissociative anesthetic, but
also has effects similar to such hallucinogens as LSD, such
stimulants as amphetamines, and such central nervous sys-
tem depressants as pentobarbital (7). Acute or subacute
PCP intoxication can cause a number of psychiatric disor-
ders, including toxic delirium, fulminant psychosis, and de-
pression (8). PCP is a drug that can make users violent,
delusional, paranoid, and catatonic and has gained notoriety
by association with numerous homicides committed by
those under its influence (9).
Previous studies suggested that PCP use increased dur-
ing the 1970s (a phase often referred to as one of ‘‘epi-
demic’’ PCP use) and peaked in the 1980s (10–12). In the
late 1980s, PCP went from being a drug used mainly by
white adolescent males and females living in suburban
areas to a drug used primarily by minority, particularly
African-American, men in their 20s and 30s, centered in a
handful of cities, particularly Washington, DC/Baltimore,
Los Angeles, New York, St. Louis, New Orleans, and
Chicago (13–16).
From January 1998 to December 2002, the Drug Abuse
Warning Network of the US Department of Health and Hu-
man Services documented an increase of more than 240% in
the number of emergency department visits related to PCP
use, from 1,725 to 4,216. DEA seizures of the drug increased
by 24% from 2000 to 2001 (17). There was discussion in the1047-2797/06/$–see front matter
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267popular media of an increase in PCP trafficking and use in
New York City (NYC), particularly in residents of NYC’s
surrounding suburbs (18). Emergency department visits re-
lated to PCP use in NYC increased by 67% from 2001 to
2002 (203 to 341 visits) (3). PCP also has been implicated
as one of the more common club drugs used by habitual
and nonhabitual drug users. A recent study of minority sub-
stance users in northern Manhattan found club-drug use to
be common (45.3% of Hispanics and 56.4% of African
Americans) and PCP to be the most commonly used club
drug, used at least once by 34.3% of respondents who had
used club drugs (19).
The 2002 National Survey on Drug Use and Health,
conducted by the Department of Health and Human Serv-
ice’s Substance Abuse and Mental Health Services Admin-
istration, reported trends in PCP use, including age of
initiation. This study showed that the number of new
PCP users by year sharply declined from 1975 to 1982
and remained low and fairly constant from 1983 to the early
1990s. From 1993 onward, the number of new users per year
began to increase again, a trend that appears to have con-
tinued (10). The Substance Abuse and Mental Health
Services Administration reported younger ages of initiation
in the early 1970s (17 to 18 years old), later ages of initia-
tion from the mid 1970s to mid 1990s (19 to 22 years old),
followed by a decrease in age of initiation back to earlier
levels from the mid 1990s through early 2000s (10). These
studies suggested a changing prevalence of PCP use during
the last 30 years. These trends could imply a return to the
earlier, more widespread pattern of PCP use seen in the
United States in the late 1970s, with the concomitant con-
cerns for public health.
A string of murders in Brooklyn and Queens in winter
2003 ultimately were blamed on PCP use, bringing the
drug to the attention of several NYC communities (9). De-
spite this increasing concern with PCP use, recent trends in
use of the drug in NYC have been largely unexamined. Be-
cause of NYC’s important place in the national portrait of
drug abuse and the lack of information on changing trends
in PCP use, we examined data from two surveys of habitual
drug users in NYC to assess potential period and birth-co-
hort effects in age at first PCP use in habitual users during
the past 40 years to identify changing trends in PCP use.
Selected Abbreviations and Acronyms
PCP Z phencyclidine
HR Z hazard ratio
CI Z confidence interval
LSD Z lysergic acid diethylamide
DEA Z Drug Enforcement Agency
IDU Z injection drug user
NIDU Z non–injection drug userMETHODS
Subject Recruitment
We used data from two surveys of street-recruited habitual
drug users in NYC. Potential participants were recruited
for two ongoing studies (19, 20) of injection drug users
(IDUs) and non-IDUs (NIDUs) by using street outreach
techniques described elsewhere (21, 22).
Briefly, outreach workers engaged drug users in conversa-
tions about ongoing studies at the research storefront and
places in the community where drugs were bought and/or
used. Both IDUs and NIDUs were recruited between August
2000 and August 2003 from three NYC boroughs in neigh-
borhoods with an active observable drug economy. Inter-
views were conducted in two storefronts in East Harlem
and the South Bronx and from a recreational vehicle parked
in Bedford-Stuyvesant in Brooklyn, Jamaica, Queensbridge
in Queens, and the Lower East Side of Manhattan. Potential
participants completed a screening demographic interview.
The IDU study was designed to study correlates and predic-
tors of hepatitis C virus infection and therefore targeted
young, recently initiated IDUs at risk for hepatitis C virus
infection. Participants were eligible for the IDU study if
they were 15 to 40 years of age and reported injecting heroin
or cocaine at least once in the last 2 months, but for no lon-
ger than 5 years. The NIDU study was designed to study cor-
relates and predictors of transition to injection drug use.
Participants were eligible for the NIDU study if they were
15 to 40 years of age and reported non–injecting drug use
of heroin or cocaine at least once per week in the last
2 months, but for no longer than 10 years, and no history
of injecting drug use. Only participants who currently
were residents of NYC were included in this analysis.
Participants were reimbursed $20 for their participation.
The institutional review board of the New York Academy of
Medicine approved the study. Informed consent was ob-
tained in writing from all study participants. Baseline data
collected through March 2004 from both the IDU and
NIDU studies were combined for this analysis.
Data Collection
After obtaining informed consent, eligible participants
completed a standardized detailed risk-behavior question-
naire administered by trained interviewers in English or
Spanish. We asked about sociodemographic characteristics,
type and frequency of drug use, sexual behaviors, and sexual
partnerships. The presence or absence of prior injection drug
use was confirmed during the interviewing process and by
phlebotomist assessment of injection stigmata (track
marks). Sociodemographic characteristics included age,
race, sex, education, recent homelessness, main income
source, and sexual identity. We examined recent frequency
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commonly used substances, including marijuana, heroin,
LSD, crack, and cocaine. Age at first use of PCP and other
substances was collected through self-report.
Statistical Methods
To ensure that all study participants had an equivalent risk
period for starting PCP use, we included only respondents 23
years and older in the analysis and considered risk for first
PCP use by age 23. The age of 23 years was used because it
was the average age of initiating PCP use plus one SD
(mean age of initiating PCP Z 19 years; SD Z 4 years).
By restricting the analysis to participants who were 23 years
or older at the interview, all participants had the full 23-year
at-risk period at the interview, and participants of all ages at
the interview had equal time in which to try PCP. All sur-
vival analysis methods make an assumption that censoring
is unrelated to the risk for the outcome within exposure
strata; given that periods and birth cohorts were key varia-
bles of interest in this analysis, these restrictions were neces-
sary to meet this assumption (23).
Initially, IDUs and NIDUs were examined separately to
assess differences in associations of interest in this analysis.
There were no substantive differences in period and birth-
cohort predictors of PCP use onset between IDUs and NI-
DUs, and as such, the groups were combined for all analyses
presented here.
We examined bivariate associations of sociodemographic
factors and drug-use behaviors with PCP use by age 23 by
using chi-square tests. Use of specific drugs (marijuana,
cocaine, heroin, crack, and LSD) was restricted to use before
the initiation of PCP use for initiators and to use before the
age of 19 years for others. The age of 19 years was selected to
assess prior drug use for those who did not use PCP because it
is the mean age of initiating PCP use in those who initiate
use, and on average, this definition will assess other drug
use up to the same age for both groups, i.e., PCP use initia-
tors and noninitiators.
We used Kaplan-Meier survival analyses to assess period
and birth-cohort effects separately. Age at first PCP use was
the incident time in analyses. The period survival plot was
stratified by date of first use of PCP: before or after 1987,
when national reports suggest that PCP use was at its lowest
(10). The birth-cohort survival plot was stratified by partic-
ipant date of birth, making four separate groupings: those
born between 1961 and 1965, 1966 and 1970, 1971 and
1975, and 1976 and 1980. Differences between curves
were determined by using log-rank tests.
We used proportional hazards models to determine the
significance of period and birth-cohort effects when control-
ling for other relevant covariates. Both the period and birth-
cohort models were adjusted for age, sex, race/ethnicity,education, any time in a juvenile detention center, and
dropping out of school. Although considering other drugs
that are associated with PCP initiation is useful in describing
the constellation of drugs that tend to be used by the same
individuals, there is no plausible mechanism that would sug-
gest these drugs themselves cause PCP use initiation, and as
such, use of other drugs was not considered a potential con-
founder in multivariable models. In addition, reinforcing
this approach, inclusion of prior drug use variables in propor-
tional hazards models did not appreciably change the rela-
tions reported in this analysis.
TABLE 1. Correlates of early initiation of PCP use
in habitual drug users in New York City
Total sample Used PCP < 23 years old
N % N % p
Total 787 100.00 292 37.10
Age (years)
!27 236 29.99 94 39.83 0.30
>27 551 70.01 198 35.93
Sex
Male 569 73.04 216 37.96 0.49
Female 210 26.96 74 35.24
Race
White 31 3.94 18 58.06 0.02
African American 277 35.20 97 35.02
Hispanic 430 54.64 153 35.58
Others 49 6.23 24 48.98
Education
!High school 417 53.19 161 38.61 0.36
>High school 367 46.81 130 35.42
Ever in juvenile
center
No 602 77.78 206 34.22 !0.01
Yes 172 22.22 83 48.26
Dropped out of
school
No 229 29.10 73 31.88 0.05
Yes 558 70.90 219 39.25
Used marijuanaa
No 77 9.78 14 18.18 !0.01
Yes 710 90.22 278 39.15
Used cocainea
No 269 34.18 107 39.78 0.26
Yes 518 65.82 185 35.71
Used heroina
No 531 67.47 198 37.29 0.88
Yes 256 32.53 94 36.72
Used cracka
No 566 71.92 204 36.04 0.32
Yes 221 28.08 88 39.82
Used lysergic acid
diethylamidea
No 622 79.03 190 30.55 !0.01
Yes 165 20.97 102 61.82
PCP Z phencyclidine.
aUsed before PCP use onset or age 19 for those who did not use PCP before age 23.
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269FIGURE 1. Kaplan-Meier survival curve of phencyclidine (PCP) use initiation before age 23 by period cohort. Log-rank test, chi-square
p ! 0.01.RESULTS
Of a total of 787 individuals from the two studies, 292
(37.1%) had used PCP by the time they were 23 years old.
In this sample of drug users, 70% of participants were 27 years
or older, 73% were male, 3.9% were white, 35.2% were
African American, and 54.6% were Hispanic (Table 1). Of
these respondents, 53.2% did not complete high school,
70.9% dropped out of school, and 22.2% spent time in a
juvenile detention center. In terms of drug use, 90.2% of
respondents had used marijuana, 65.8% had used cocaine,
32.5% had used heroin, 28.1% had used crack, and 21.0%
had used LSD.
Bivariate correlates of PCP use by age 23 were race
(58.1% of whites, 35.0% of African Americans, 35.6% of
Hispanics, and 49.0% of those of other races; p Z 0.02)
and having been in a juvenile center (48.3% of those who
had versus 34.2% of those who had not; p ! 0.01). Of prior
TABLE 2. Proportional hazards model predicting time to PCP








Period ! 1987a 3.55 0.25 !0.01 34.77 21.45–56.36
Age 0.20 0.02 !0.01 0.82 0.79–0.85
Female 0.16 0.14 0.28 0.86 0.64–1.14
African Americanb 0.78 0.27 !0.01 0.46 0.27–0.78
Hispanicb 0.71 0.26 0.01 0.49 0.30–0.82
Othersb 0.09 0.32 0.77 0.91 0.49–1.70
> High school 0.04 0.15 0.80 0.96 0.72–1.30
Ever in juvenile center 0.53 0.14 !0.01 1.69 1.29–2.22
Dropped out of school 0.29 0.17 0.10 1.34 0.95–1.88
PCP Z phencyclidine.
aPeriod > 1987 is reference group.
bWhite is reference group.drug use variables, marijuana (39.2% versus 18.2%; p !
0.01) and LSD (61.8% versus 30.6%; p ! 0.01) were associ-
ated positively with PCP use.
Kaplan-Meier survival curves by period, stratified before
and after 1987, are shown in Fig. 1. This figure shows that
risk for PCP initiation by age 23 was greater before 1987
than after 1987 (log-rank test, p ! 0.01).
A proportional hazards model comparing the likelihood
of having tried PCP at any age up to 23 years for the period
up to 1987 and the period after 1987 shows that two varia-
bles were significantly associated with increased risk for us-
ing PCP by age 23: earlier period (hazard ratio [HR] Z
34.77; 95% confidence interval [CI], 21.45–56.36) and hav-
ing ever been in a juvenile center (HR Z 1.69; 95% CI,
1.29–2.22; Table 2). Other variables associated with a signif-
icantly decreased risk for PCP use were age at time of inter-
view (HR Z 0.82; 95% CI, 0.79–0.85), African-American
race (HR Z 0.46; 95% CI, 0.27–0.78), and Hispanic race
(HR Z 0.49; 95% CI, 0.30–0.82).
Kaplan-Meier survival curves by birth cohort, stratified
by birth-year groups 1961 to 1965, 1966 to 1970, 1971 to
1975, and 1976 to 1980, are shown in Fig. 2. Test for equality
of survival curves by birth cohort showed a significant differ-
ence (log-rank test, p Z 0.03). A second test comparing the
1971 to 1975 birth cohort with the others showed the differ-
ence to be significant (log-rank test, p ! 0.01). This figure
shows that those born in the 1971 to 1975 birth cohort gen-
erally had lower risk for initiation of PCP use by age 23.
In a proportional hazards model predicting risk for PCP
use by age 23, compared with those born in 1976 to 1980,
those born in 1971 to 1975 had decreased risk for using
PCP through age 23 (HR Z 0.58; 95% CI, 0.37–0.91;
Table 3). Compared with white respondents, African-
American and Hispanic respondents had lower risks for us-
ing PCP (HR Z 0.38; 95% CI, 0.22–0.65 and HR Z 0.41;
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270FIGURE 2. Kaplan-Meier survival curve of phencyclidine (PCP) use initiation before age 23 by birth cohort. Log-rank test,
chi-square p ! 0.01.95% CI, 0.24–0.68, respectively). Time in a juvenile deten-
tion center also was associated with increased risk for PCP
use by age 23 (HR Z 1.68; 95% CI, 1.28–2.20).
DISCUSSION
We documented period effects and birth-cohort effects on
risk for early initiation of PCP use in a group of predomi-
nantly minority street-recruited drug users in NYC. Risk
for PCP initiation by age 23 was greater before 1987 than
after 1987. In addition, participants born during 1971 to
1975 had the lowest risk for initiating use of PCP at a given
age. Positive predictors for PCP use by age 23 were white
race (compared with African-American and Hispanic
race) and having been in a juvenile detention center.
Our results are consistent with other observations that
there has been a change over time in PCP use initiation in
young people (10, 11, 13, 15). Before 1987, a greater per-
centage of drug users in our cohort had used PCP by age
23 than after 1987. We also found that different birth
cohorts had differing likelihoods of early initiation of use.
Although the primary focus of public health interventions
during the past three decades has been on prevention of ad-
olescent and young adult initiation of PCP (15), we found
that risk for early initiation of PCP use was decreasing
throughout the 1970s and 1980s (15, 24). Although we
are not aware of other recent work that explicitly assessed
period and birth-cohort effects on PCP use patterns, other
reports provided evidence that corroborates our findings.
In 1978, national reports found that average age of first
use of PCP was approximately 13 years (25). From 1976 to
1987, the number of high school seniors reporting PCP
use in the prior 30 days and the number of 12- to 17-year-
olds reporting ever having used PCP steadily declined
(26). From 1979 to 1982, the number of 18- to 25-year-olds reporting having used PCP declined from 14.5% to
10.5%, and concurrently, the age of emergency department
patients making visits because of PCP use increased (26).
Subsequently, from 1979 to 1987, the percentage of
American high school seniors reporting ever having tried
PCP decreased from 12.8% to 3% (27). This decline in use
in young people seems to have continued through the late
1980s and early 1990s and is consistent with our observation
of a birth-cohort effect in risk for early PCP use initiation.
It was suggested that PCP use follows cyclical trends,
declining when a new generation of users experiences the
drug’s side effects. Other factors implicated in periodic
declines in rates of use are intense public health campaigns
warning of the drug’s effects, targeted primarily at children
and adolescents; restrictions on the purchase of pyridine
(a necessary ingredient for the manufacture of PCP); and
government crackdowns on production and possession of
TABLE 3. Proportional hazards model predicting time to PCP








Born 1961–1965a 0.31 0.56 0.58 0.74 0.25–2.20
Born 1966–1970a 0.38 0.38 0.33 0.69 0.32–1.45
Born 1971–1975a 0.55 0.23 0.02 0.58 0.37–0.90
Age 0.04 0.04 0.33 1.04 0.96–1.12
Female 0.14 0.15 0.35 0.87 0.66–1.16
Blackb 0.97 0.27 !0.01 0.38 0.22–0.65
Hispanicb 0.90 0.27 !0.01 0.41 0.24–0.68
Othersb 0.36 0.32 0.26 0.70 0.37–1.31
> High school 0.07 0.15 0.64 0.93 0.70–1.25
Ever in juvenile center 0.52 0.14 !0.01 1.68 1.28–2.20
Dropped out of school 0.27 0.17 0.12 1.31 0.93–1.84
aBorn 1976 to 1980 is reference group.
bWhite is reference group.
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271the drug, as well as movement of the drug from a DEA sched-
ule III classification to a place on the more tightly regulated
schedule II (the same schedule as cocaine) (26, 28). In met-
ropolitan areas, in which PCP use appears to have remained
concentrated, amount of PCP use appears to be related to
factors governing the consumption of ‘‘more highly
coveted’’ drugs, such as crack cocaine (15). Price and ease
of acquisition of those more desirable drugs may drive PCP
use trends (15).
The degree to which our results are generalizable outside
NYC is unknown, and these changes in PCP use may be con-
fined to this geographic area of study. We note that other
work in the Washington, DC/Baltimore area generally
found rates of PCP use to be greater than in New York
and showed an increase in PCP use since the late 1990s
(3). We do not know if our observations of period and birth
cohorts are generalizable to other different demographic
groups than those studied here. Also, period and birth-
cohort effects may differ between subsets of drug users. For
example, persons who predominantly buy and use PCP on
the street may be different than those who predominantly
buy and use PCP in clubs. However, we note that our find-
ings highlight the more general phenomenon of a particular
drug’s rise and fall over time. This may be important to con-
sider in the context of drug use surveillance and prediction.
Although PCP and methamphetamines are often consid-
ered club drugs, they also often are sold in the streets (5, 19).
We do not have information on this to assess whether PCP
use was within a club or in another context. Recent reports
suggested that club drugs are being purchased increasingly
on the street, something that would need to be considered
in basing interventions on these findings (29, 30). This study
focuses on habitual drug users. It is possible that more casual
recreational users make up the bulk of the increase in PCP
use seen in the past decade, and that these users follow
different age and demographic patterns than those docu-
mented here. Our sample is predominantly male. It was sug-
gested that female PCP users are different in their reasons for
initiating and continuing to use PCP (6), and as such, our
results must be generalized with caution to populations
with different demographic composition.
Notwithstanding these limitations, our data suggest
a changing likelihood of PCP use by a given age during dif-
ferent periods and among different birth cohorts of habitual
drug users in NYC during the past 30 years. Those who ini-
tiated PCP use after 1987, when PCP popularity was at its
nadir, were less likely to have initiated PCP use by age 23
than those who initiated use before 1987. Understanding
secular trends in club-drug use patterns is essential for
designing effective risk-reduction interventions and to iden-
tify likely patterns in cohorts at risk for using these drugs in
the future. Period and birth-cohort effects may be present in
the use of other drugs over time; understanding suchpatterns may be important for efforts aimed at surveillance,
prediction, and minimizing use of illicit drugs.
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